Δ


Journal

Journal of inherited metabolic disease
ISSN: 1573-2665
Titre abrégé: J Inherit Metab Dis
Pays: United States
ID NLM: 7910918

Informations de publication

Date de publication:
07 2020
Historique:
received: 04 10 2019
revised: 13 01 2020
accepted: 30 01 2020
pubmed: 6 2 2020
medline: 24 8 2021
entrez: 5 2 2020
Statut: ppublish

Résumé

The bifunctional homooligomeric enzyme Δ

Identifiants

pubmed: 32017139
doi: 10.1002/jimd.12220
doi:

Substances chimiques

Urea 8W8T17847W
ALDH18A1 protein, human EC 1.2.1.3
Aldehyde Dehydrogenase EC 1.2.1.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

657-670

Informations de copyright

© 2020 SSIEM.

Références

Kamoun P, Aral B, Saudubray JM. A new inherited metabolic disease: Δ1-pyrroline 5-carboxylate synthetase deficiency. Bull Acad Natle Med. 1998;182:131-139.
Baumgartner MR, Hu CA, Almashanu S, et al. Hyperammonemia with reduced ornithine, citrulline, arginine and proline: a new inborn error caused by a mutation in the gene encoding Δ1-pyrroline-5-carboxylate synthase. Hum Mol Genet. 2000;9:2853-2858.
Baumgartner MR, Rabier D, Nassogne MC, et al. Δ1-pyrroline-5-carboxylate synthase deficiency: neurodegeneration, cataracts and connective tissue manifestations combined with hyperammonaemia and reduced ornithine, citrulline, arginine and proline. Eur J Pediatr. 2005;164:31-36.
Bicknell LS, Pitt J, Aftimos S, Ramadas R, Maw MA, Robertson SP. A missense mutation in ALDH18A1, encoding Δ1-pyrroline-5-carboxylate synthase (P5CS), causes an autosomal recessive neurocutaneous syndrome. Eur J Hum Genet. 2008;16:1176-1186.
Skidmore DL, Chitayat D, Morgan T, et al. Further expansion of the phenotypic spectrum associated with mutations in ALDH18A1, encoding Δ1-pyrroline-5-carboxylate synthase (P5CS). Am J Med Genet A. 2011;155A:1848-1856.
Zampatti S, Castori M, Fischer B, et al. De Barsy syndrome: a genetically heterogeneous autosomal recessive cutis laxa syndrome related to P5CS and PYCR1 dysfunction. Am J Med Genet A. 2012;158A:927-931.
Gardeitchik T, Mohamed M, Fischer B, et al. Clinical and biochemical features guiding the diagnostics in neurometabolic cutis laxa. Eur J Hum Genet. 2014;22:888-895.
Wolthuis DF, van Asbeck E, Mohamed M, et al. Cutis laxa, fat pads and retinopathy due to ALDH18A1 mutation and review of the literature. Eur J Paediatr Neurol. 2014;18:511-515.
Handley MT, Mégarbané A, Meynert AM, et al. Loss of ALDH18A1 function is associated with a cellular lipid droplet phenotype suggesting a link between autosomal recessive cutis laxa type 3A and Warburg micro syndrome. Mol Genet Genomic Med. 2014;2:319-325.
Fischer B, Callewaert B, Schröter P, et al. Severe congenital cutis laxa with cardiovascular manifestations due to homozygous deletions in ALDH18A1. Mol Genet Metab. 2014;112:310-316.
Stavropoulos DJ, Merico D, Jobling R, et al. Whole genome sequencing expands diagnostic utility and improves clinical management in pediatric medicine. NPJ Genom Med. 2016;1:15012.
Alazami AM, Al-Qattan SM, Faqeih E, et al. Expanding the clinical and genetic heterogeneity of hereditary disorders of connective tissue. Hum Genet. 2016;135:525-540.
Smigiel R, Kusmierska K, Pollak A, et al. Severe phenotype of De Barsy syndrome in two siblings with novel mutations in the ALDH18A1 gene. J Clin Med Genomics. 2017;5:1.
Lefebvre M, Beaufrere AM, Francannet C, et al. Extending the ALDH18A1 clinical spectrum to severe autosomal recessive fetal cutis laxa with corpus callosum agenesis. Am J Med Genet A. 2018;176:2509-2512.
Martinelli D, Häberle J, Rubio V, et al. Understanding pyrroline-5-carboxylate synthetase deficiency: clinical, molecular, functional, and expression studies, structure-based analysis, and novel therapy with arginine. J Inherit Metab Dis. 2012;35:761-776.
Fischer-Zirnsak B, Escande-Beillard N, Ganesh J, et al. Recurrent de novo mutations affecting residue Arg138 of pyrroline-5-carboxylate synthase cause a progeroid form of autosomal-dominant cutis laxa. Am J Hum Genet. 2015;97:483-492.
Nozaki F, Kusunoki T, Okamoto N, et al. ALDH18A1-related cutis laxa syndrome with cyclic vomiting. Brain Dev. 2016;38:678-684.
Bhola PT, Hartley T, Bareke E, et al. Autosomal dominant cutis laxa with progeroid features due to a novel, de novo mutation in ALDH18A1. J Hum Genet. 2017;62:661-663.
Coutelier M, Goizet C, Durr A, et al. Alteration of ornithine metabolism leads to dominant and recessive hereditary spastic paraplegia. Brain. 2015;138:2191-2205.
Panza E, Escamilla-Honrubia JM, Marco-Marín C, et al. ALDH18A1 gene mutations cause dominant spastic paraplegia SPG9: loss of function effect and plausibility of a dominant negative mechanism. Brain. 2016;139:e3.
Slavotinek AM, Pike M, Mills K, Hurst JA. Cataracts, motor system disorder, short stature, learning difficulties, and skeletal abnormalities: a new syndrome? Am J Med Genet. 1996;62:42-47.
Seri M, Cusano R, Forabosco P, et al. Genetic mapping to 10q23.3-q24.2, in a large Italian pedigree, of a new syndrome showing bilateral cataracts, gastroesophageal reflux, and spastic paraparesis with amyotrophy. Am J Hum Genet. 1999;64:586-593.
Kremer LS, Bader DM, Mertes C, et al. Genetic diagnosis of mendelian disorders via RNA sequencing. Nat Commun. 2017;8:15824.
Steenhof M, Kibaek M, Larsen MJ, et al. Compound heterozygous mutations in two different domains of ALDH18A1 do not affect the amino acid levels in a patient with hereditary spastic paraplegia. Neurogenetics. 2018;19:145-149.
Koh K, Ishiura H, Beppu M, et al. Novel mutations in the ALDH18A1 gene in complicated hereditary spastic paraplegia with cerebellar ataxia and cognitive impairment. J Hum Genet. 2018;63:1009-1013.
Magini P, Marco-Marin C, Escamilla-Honrubia JM, et al. P5CS expression study in a new family with ALDH18A1-associated hereditary spastic paraplegia SPG9. Ann Clin Transl Neurol. 2019;6:1533-1540.
Wei Q, Dong HL, Pan LY, et al. Clinical features and genetic spectrum in Chinese patients with recessive hereditary spastic paraplegia. Transl Neurodegener. 2019;8:19.
Valle D, Simell O. The hyperornithinemias. In: Scriver CR, Beaudet AL, Sly WS, et al., eds.The Metabolic and Molecular Bases of Inherited Disease, 8th. New York, NY: McGraw-Hill Medical; 2001:1857-1895.
Köhler ES, Sankaranarayanan S, van Ginneken CJ, et al. The human neonatal small intestine has the potential for arginine synthesis; developmental changes in the expression of arginine-synthesizing and -catabolizing enzymes. BMC Dev Biol. 2008;8:107.
van de Poll MC, Siroen MP, van Leeuwen PA, et al. Interorgan amino acid exchange in humans: consequences for arginine and citrulline metabolism. Am J Clin Nutr. 2007;85:167-172.
Hu CA, Lin WW, Obie C, Valle D. Molecular enzymology of mammalian Δ1-pyrroline-5-carboxylate synthase. Alternative splice donor utilization generates isoforms with different sensitivity to ornithine inhibition. J Biol Chem. 1999;274:6754-6762.
Hamano Y, Kodama H, Fujikawa Y, Tanaka Y, Nishimura K, Yanagisawa M. Use of immunocytochemical analysis of a duodenal biopsy specimen to identify a carrier of ornithine transcarbamylase deficiency. N Engl J Med. 1988;318:1521-1523.
Caldovic L, Morizono H, Gracia Panglao M, et al. Cloning and expression of the human N-acetylglutamate synthase gene. Biochem Biophys Res Commun. 2002;299:581-586.
Seddon AP, Zhao KY, Meister A. Activation of glutamate by gamma-glutamate kinase: formation of gamma-cis-cycloglutamyl phosphate, an analog of gamma-glutamyl phosphate. J Biol Chem. 1989;264:11326-11335.
Phang JM, Hu CA, Valle D. Disorders of proline and hydroxyproline metabolism. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill Medical; 2001:1821-1838.
Reversade B, Escande-Beillard N, Dimopoulou A, et al. Mutations in PYCR1 cause cutis laxa with progeroid features. Nat Genet. 2009;41:1016-1021.
Zaki MS, Bhat G, Sultan T, et al. PYCR2 mutations cause a lethal syndrome of microcephaly and failure to thrive. Ann Neurol. 2016;80:59-70.
Wu G, Bazer FW, Burghardt RC, et al. Proline and hydroxyproline metabolism: implications for animal and human nutrition. Amino Acids. 2011;40:1053-1063.
Kretz R, Bozorgmehr B, Kariminejad MH, et al. Defect in proline synthesis: pyrroline-5-carboxylate reductase 1 deficiency leads to a complex clinical phenotype with collagen and elastin abnormalities. J Inherit Metab Dis. 2011;34:731-739.
Kardos GR, Wastyk HC, Robertson GP. Disruption of proline synthesis in melanoma inhibits protein production mediated by the GCN2 pathway. Mol Cancer Res. 2015;13:1408-1420.
Sinnige PF, van Ravenswaaij-Arts CMA, Caruso P, et al. Imaging in cutis laxa syndrome caused by a dominant negative ALDH18A1 mutation, with hypotheses for intracranial vascular tortuosity and wide perivascular spaces. Eur J Paediatr Neurol. 2017;21:912-920.
Panza E, Martinelli D, Magini P, Dionisi Vici C, Seri M. Hereditary spastic paraplegia is a common phenotypic finding in ARG1 deficiency, P5CS deficiency and HHH syndrome: three inborn errors of metabolism caused by alteration of an interconnected pathway of glutamate and urea cycle metabolism. Front Neurol. 2019;10:131.
Olivieri G, Pro S, Diodato D, et al. Corticospinal tract damage in HHH syndrome: a metabolic cause of hereditary spastic paraplegia. Orphanet J Rare Dis. 2019;14:208.
Pendeville H, Carpino N, Marine JC, et al. The ornithine decarboxylase gene is essential for cell survival during early murine development. Mol Cell Biol. 2001;21:6549-6558.
Phang JM. Proline metabolism in cell regulation and cancer biology: recent advances and hypotheses. Antioxid Redox Signal. 2019;30:635-649.
Jukkola A, Kauppila S, Risteli L, et al. New lethal disease involving type I and III collagen defect resembling geroderma osteodysplastica, De Barsy syndrome, and Ehlers-Danlos syndrome IV. J Med Genet. 1998;35:513-518.
Marco-Marín C, Gil-Ortiz F, Pérez-Arellano I, Cervera J, Fita I, Rubio V. A novel two-domain architecture within the amino acid kinase enzyme family revealed by the crystal structure of Escherichia coli glutamate 5-kinase. J Mol Biol. 2007;367:1431-1446.

Auteurs

Clara Marco-Marín (C)

Instituto de Biomedicina de Valencia of the CSIC, Valencia, Spain.
Centro para Investigación Biomédica en Red sobre Enfermedades Raras CIBERER-ISCIII, Valencia, Spain.

Juan M Escamilla-Honrubia (JM)

Instituto de Biomedicina de Valencia of the CSIC, Valencia, Spain.
Centro para Investigación Biomédica en Red sobre Enfermedades Raras CIBERER-ISCIII, Valencia, Spain.

José L Llácer (JL)

Instituto de Biomedicina de Valencia of the CSIC, Valencia, Spain.
Centro para Investigación Biomédica en Red sobre Enfermedades Raras CIBERER-ISCIII, Valencia, Spain.

Marco Seri (M)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Medical Genetics Unit, S. Orsola-Malpighi University Hospital, Bologna, Italy.

Emanuele Panza (E)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Vicente Rubio (V)

Instituto de Biomedicina de Valencia of the CSIC, Valencia, Spain.
Centro para Investigación Biomédica en Red sobre Enfermedades Raras CIBERER-ISCIII, Valencia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH